Kbc Group Nv Collegium Pharmaceutical, Inc Transaction History

Kbc Group Nv

$33.1 Billion
Q3 2024

A detailed history of Kbc Group Nv transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Kbc Group Nv holds 1,354 shares of COLL stock, worth $41,297. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,354

Previous 1,354 -0.0%

Holding current value

$41,297

Previous $44,000 18.18%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$21.16 - $30.8 $29,348 - $42,719	-1,387 Reduced 50.6%	1,354 $42,000
Q3 2023 Feb 15, 2024	SELL	$21.23 - $24.28 $23,395 - $26,756	-1,102 Reduced 40.2%	1,639 $37,000
Q2 2023 Feb 15, 2024	SELL	$21.06 - $24.0 $12,930 - $14,736	-614 Reduced 18.3%	2,741 $59,000
Q1 2023 Feb 14, 2024	SELL	$23.0 - $29.88 $14,122 - $18,346	-614 Reduced 18.3%	2,741 $66,000
Q1 2023 May 04, 2023	SELL	$23.0 - $29.88 $14,122 - $18,346	-614 Reduced 18.3%	2,741 $66,000
Q3 2022 Feb 15, 2024	BUY	$15.46 - $20.1 $30,935 - $40,220	2,001 Added 147.78%	3,355 $54,000
Q2 2022 Feb 14, 2024	SELL	$14.22 - $20.88 $218,504 - $320,842	-15,366 Reduced 82.08%	3,355 $59,000
Q2 2022 Jul 26, 2022	SELL	$14.22 - $20.88 $218,504 - $320,842	-15,366 Reduced 82.08%	3,355 $59,000
Q4 2021 Feb 14, 2024	BUY	$17.5 - $21.35 $303,922 - $370,785	17,367 Added 1282.64%	18,721 $350,000
Q4 2021 Feb 03, 2022	BUY	$17.5 - $21.35 $174,020 - $212,304	9,944 Added 113.3%	18,721 $350,000
Q3 2021 Nov 10, 2021	BUY	$17.75 - $25.39 $155,791 - $222,848	8,777 New	8,777 $173,000

Others Institutions Holding COLL

# of Institutions

256

Shares Held

38.6M

Call Options Held

100K

Put Options Held

21.1K

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.04B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account